Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02289417
Registration number
NCT02289417
Ethics application status
Date submitted
10/11/2014
Date registered
13/11/2014
Date last updated
7/05/2020
Titles & IDs
Public title
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
Query!
Scientific title
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Query!
Secondary ID [1]
0
0
2014-002981-64
Query!
Secondary ID [2]
0
0
CC-10004-UC-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
UC
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Apremilast
Treatment: Drugs - Placebo
Experimental: Apremilast 30 mg PO BID - Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks
After 12 weeks:
Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)
Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)
After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)
Experimental: Apremilast 40 mg PO BID - Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks
After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)
After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)
Placebo Comparator: Placebo BID - Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)
After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)
Treatment: Drugs: Apremilast
Treatment: Drugs: Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12
Query!
Assessment method [1]
0
0
Clinical remission was defined as a total Mayo score = 2 points, with no individual subscore exceeding 1 point. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.
Stool Frequency Subscore (SFS)
Rectal Bleeding Subscore (RBS)
Endoscopy Subscore
Physician's Global Assessment (PGA). Two-sided 95% confidence intervals (CI) for the within-group percentages are based on the Wilson score method.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12
Query!
Assessment method [1]
0
0
Clinical response was defined as a decrease from baseline in the TMS of at least 3 points and at least 30%, along with a reduction in the rectal bleeding subscore (RBS) of at least 1 point or an absolute RBS of = 1. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.
Stool Frequency Subscore (SFS)
Rectal Bleeding Subscore
Endoscopy Subscore
Physician's Global Assessment (PGA)
Rectal bleeding (subscore 0-3) was defined as:
0 = No blood seen
= Streaks of blood with stool less than half the time
= Obvious blood with stool
= Blood alone passes Two-sided 95% CI for the within-group percentages are based on the Wilson score method.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Achieved an Endoscopic Remission at Week 12
Query!
Assessment method [2]
0
0
An endoscopic remission was defined as a Mayo endoscopic subscore (MES) of 0 at Week 12.
The MES subscore findings were defined as:
0 = Normal or inactive disease
= Mild Disease (erythema, decreased vascular pattern, mild friability)
= Moderate Disease (marked erythema, lack of vascular pattern, friability erosions)
= Severe Disease (spontaneous bleeding, ulceration)
The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Percentage of Participants Who Achieved an Endoscopic Response at Week 12
Query!
Assessment method [3]
0
0
An endoscopic response is defined as a decrease from baseline of at least 1 point in the MES at Week 12. The Mayo endoscopy subscore findings were defined as:
0 = Normal or inactive disease
= Mild Disease (erythema, decreased vascular pattern, mild friability)
= Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3 = Severe Disease (spontaneous bleeding, ulceration).
The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.
Query!
Timepoint [3]
0
0
Week 12
Query!
Secondary outcome [4]
0
0
Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of = 1 at Week 12
Query!
Assessment method [4]
0
0
The RBS was measured as:
0 = No blood seen
= Streaks of blood with stool less than half the time
= Obvious blood with stool most of the time
= Blood alone passes
The daily bleeding score represents the most severe bleeding of the day. Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Query!
Timepoint [4]
0
0
Week 12
Query!
Secondary outcome [5]
0
0
Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12
Query!
Assessment method [5]
0
0
Clinical remission was defined as a modified Mayo score of = 2, with no individual subscore > 1, at Week 12. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.
Query!
Timepoint [5]
0
0
Week 12
Query!
Secondary outcome [6]
0
0
Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12
Query!
Assessment method [6]
0
0
Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS = 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity.
The RBS was measured as:
0 = No blood seen
= Streaks of blood with stool less than half the time
= Obvious blood with stool most of the time
= Blood alone passes
The daily bleeding score represents the most severe bleeding of the day. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.
Query!
Timepoint [6]
0
0
Week 12
Query!
Secondary outcome [7]
0
0
Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8
Query!
Assessment method [7]
0
0
Clinical remission in the partial Mayo subscore was defined as a PMS of 2 points or lower, with no individual subscore >1. The PMS is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores:
Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).
Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Query!
Timepoint [7]
0
0
Week 8
Query!
Secondary outcome [8]
0
0
Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8
Query!
Assessment method [8]
0
0
Clinical response in the PMS was defined as a decrease from baseline in PMS of at least 2 points and at least 25%, with an accompanying decrease in the RBS of at least 1 point or an absolute RBS of 0 or 1. The PMS score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores:
Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).
Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Query!
Timepoint [8]
0
0
Week 8
Query!
Secondary outcome [9]
0
0
The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase
Query!
Assessment method [9]
0
0
A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
Query!
Timepoint [9]
0
0
From the first dose of investigational product (IP) and no later than 28 days after the last dose of IP for those who had completed the study or discontinued (D/C) early; maximum duration of exposure to treatment was 12.00 weeks
Query!
Secondary outcome [10]
0
0
The Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period
Query!
Assessment method [10]
0
0
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain.
Query!
Timepoint [10]
0
0
From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early; median duration of exposure to treatment was 12.00 weeks
Query!
Secondary outcome [11]
0
0
The Number of Participants Who Experienced TEAEs During the Apremilast (APR) Exposure Period (Active Treatment Phase) Through Week 52
Query!
Assessment method [11]
0
0
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
Query!
Timepoint [11]
0
0
From first dose of IP and no later than 28 days after last dose of IP for those who completed the active treatment phase or D/C early; median duration of exposure = 41.00, 44.15 and 40.00 weeks respectively for 30 mg, 40 mg and 30 mg/40 mg APR arms
Query!
Secondary outcome [12]
0
0
The Number of Participants Who Experienced TEAEs During Week 52 to Week 104 (Extension Phase)
Query!
Assessment method [12]
0
0
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
Query!
Timepoint [12]
0
0
From the first dose of IP at Week 52 and no later than 28 days after the last dose of IP for those who completed the study or had discontinued early; median exposure of apremilast for the total apremilast group was 52 weeks.
Query!
Eligibility
Key inclusion criteria
Subjects must satisfy the following criteria to be enrolled in the study:
- Male or female aged 18 and over at the time of signing the informed consent.
- Must understand and voluntarily sign an informed consent form prior to any study
related assessments/procedures being conducted.
- Diagnosis of ulcerative colitis (UC) with a duration of at least 3 months prior to the
Screening Visit..
- Total Mayo Score (TMS) = 6 to = 11 (range: 0-12) at baseline, prior to randomization
in the study.
- Endoscopic subscore = 2 (range: 0-3) on the Mayo score prior to randomization in the
study.
- Subjects must have had a therapeutic failure, been intolerant to, or have a
contraindication to, at least one of the following: oral aminosalicylates (ie,
5-aminosalicylic acid [5-ASA] compounds or sulfasalazine [SSZ]), budesonide, systemic
corticosteroids, or immunosuppressants (eg, 6-mercaptopurine [6-MP], azathioprine
[AZA], or methotrexate [MTX]).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
The presence of any of the following will exclude a subject from enrollment:
- Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic
colitis, radiation colitis or diverticular disease-associated colitis.
- Ulcerative colitis restricted to the distal 15 cm or less (eg, ulcerative proctitis).
- Subjects who have had surgery as a treatment for UC or who, in the opinion of the
Investigator, are likely to require surgery for UC during the study.
- Clinical signs suggestive of fulminant colitis or toxic megacolon.
- Prior use of any tumor necrosing factor (TNF) inhibitor (or any biologic agent).
- Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine or thalidomide.
- Use of intravenous (IV) corticosteroids within 2 weeks of the Screening Visit.
- Use of immunosuppressants (AZA, 6-MP or MTX) within 8 weeks of the Screening Visit.
- Use of topical treatment with 5-ASA or corticosteroid enemas or suppositories within 2
weeks of the Screening Visit.
- History of any clinically significant neurological, renal, hepatic, gastrointestinal,
pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder
or disease, or any other medical condition that, in the investigator's opinion, would
preclude participation in the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/01/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
3/06/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
170
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [3]
0
0
Mater Adult Hospital - South Brisbane
Query!
Recruitment hospital [4]
0
0
Footscray Hospital - Footscray
Query!
Recruitment hospital [5]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [5]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Mississippi
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Utah
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Washington
Query!
Country [17]
0
0
Bulgaria
Query!
State/province [17]
0
0
Plovdiv
Query!
Country [18]
0
0
Bulgaria
Query!
State/province [18]
0
0
Sofia
Query!
Country [19]
0
0
Bulgaria
Query!
State/province [19]
0
0
Varna
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Manitoba
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Ontario
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Brno
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Hradec Kralove
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Hradec Králové
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Slany
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Amiens
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Clichy
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Nantes
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Nice
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Pierre Bénite
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Saint Priest en Jarez
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Vandoeuvre les Nancy
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Berlin
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Frankfurt
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Keil
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Minden
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Budapest
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Debrecen
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Mosonmagyaróvár
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Szeged
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Szekszárd
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Vác
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Bologna
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Milan
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Palermo
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Roma
Query!
Country [47]
0
0
Netherlands
Query!
State/province [47]
0
0
Groningen
Query!
Country [48]
0
0
Netherlands
Query!
State/province [48]
0
0
Rotterdam
Query!
Country [49]
0
0
New Zealand
Query!
State/province [49]
0
0
Auckland
Query!
Country [50]
0
0
New Zealand
Query!
State/province [50]
0
0
Christchurch
Query!
Country [51]
0
0
New Zealand
Query!
State/province [51]
0
0
Dunedin
Query!
Country [52]
0
0
New Zealand
Query!
State/province [52]
0
0
Hamilton
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Bialystok
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Bydgoszcz
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Czestochowa
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Katowice
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Sopot
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Szczecin
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Torun
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Warsaw
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Warszawa
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Wroclaw
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Kazan
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Moscow
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Rostov on Don
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Saratov
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
St Petersburg
Query!
Country [68]
0
0
Ukraine
Query!
State/province [68]
0
0
Ivano-Frankivsk
Query!
Country [69]
0
0
Ukraine
Query!
State/province [69]
0
0
Kharkiv
Query!
Country [70]
0
0
Ukraine
Query!
State/province [70]
0
0
Kirovograd
Query!
Country [71]
0
0
Ukraine
Query!
State/province [71]
0
0
Kremenchuk
Query!
Country [72]
0
0
Ukraine
Query!
State/province [72]
0
0
Lviv
Query!
Country [73]
0
0
Ukraine
Query!
State/province [73]
0
0
Odesa
Query!
Country [74]
0
0
Ukraine
Query!
State/province [74]
0
0
Uzhgorod
Query!
Country [75]
0
0
Ukraine
Query!
State/province [75]
0
0
Vinnytsia
Query!
Country [76]
0
0
Ukraine
Query!
State/province [76]
0
0
Zaporizhzhia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of
apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants
with active Ulcerative Colitis (UC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02289417
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02289417
Download to PDF